Wins business from Carl Zeiss Meditec, R2 Technology, Biomerica and Immucor
Westborough, MA, September 22, 2003 – GlobalVision International, Inc. today announced that its hybrid localization methodology has proven successful at many global Medical companies. Efficiencies in the order of 20-30% are gained leading to similar reductions in costs.
By integrating the top-down and bottom-up translation-reuse processes and applying the company’s knowledge gained from high-tech fields in Electronics, Manufacturing, Software, Test and Measurement, GlobalVision succeeded in meeting the quality, schedule and cost needs of its newly acquired clients: Carl Zeiss Meditec, R2 Technology, Biomerica and Immucor.
Additionally, GlobalVision’s offices in the USA, Europe, Asia and the Middle-East, give the company access to abundant in-country translators specialized in Medical-technology fields, enabling its rapid business growth in those fields.
“Accurate translations relating to technical subjects involving electronics, software, precision, imaging, diagnostics, detection and testing are high priorities to our international clients and users,” said Ken Miller, Chief Operating Officer at R2 Technology. “GlobalVision’s unique process enabled it to perform all its promises despite strict schedules and budgets”.
“We are very impressed with GlobalVision’s professional approach to localization”, said W. Kevin Liddle, Ph.D., Director of Operations at Biomerica, Inc. “They never have to re-invent the wheel or re-translate text that is already translated. Our product-update localization efforts and costs have gone down by as much as 30%”.
“Medical companies can now join the rest of the high-tech companies when it comes to fulfilling their translation and localization needs”, said Nabil Freij, President of GlobalVision International, Inc. “Meeting the language requirements of international users is now easier than ever. Any company with a global vision ought to look into our translation process.”